Tokyo, Japan | Fund Name | Location |
| CICC Wealth Management | China, Guangdong, Shenzhen |
| Core Capital Partners LLP | England, London, United Kingdom |
| Domo Investment | Chengdu, China, Sichuan |
| European Medical Cannabis Group | - |
| F3F | - |
| Federated Kaufmann Fund | - |
| Huaman Chuangmeng | China, Ningbo, Zhejiang |
| INCapital Ventures | Canada, Ontario, Toronto |
| Klein Private Equity Investment | - |
| Nizar AlNusif Sons Holding | - |
| Philippine National Bank | Pasay, Pasay City, Philippines |
| Princeton Biopharma Capital Partners | New York, New York, United States |
| Revolution Health | District of Columbia, United States, Washington |
| Sharq Ventures House | - |
| Sprint | Kansas, Overland Park, United States |
| The Baobab Network | England, London, United Kingdom |
| United Internet Ventures | Germany, Rheinland-Pfalz, Rhineland-Palatinate |
| University of Central Florida Business Incubation Program | Florida, Orlando, United States |
| Wanxiang America | Elgin, Illinois, United States |
| Yike Zongheng | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AuB | $2M | 24 Sep 2019 | Chiyoda, Japan | ||
Quentis Therapeutics | $48M | 27 Feb 2018 | New York, New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AuB | $2M | 24 Sep 2019 | Chiyoda, Japan | ||
Quentis Therapeutics | $48M | 27 Feb 2018 | New York, New York, United States |
